Compare ENPH & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENPH | TVTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.3B |
| IPO Year | 2011 | 2013 |
| Metric | ENPH | TVTX |
|---|---|---|
| Price | $38.63 | $65.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 13 |
| Target Price | ★ $41.30 | $40.62 |
| AVG Volume (30 Days) | ★ 4.3M | 1.6M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.00 | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | N/A |
| Revenue This Year | N/A | $44.76 |
| Revenue Next Year | $9.81 | $35.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $17.05 |
| 52 Week High | $73.74 | $66.24 |
| Indicator | ENPH | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 67.55 |
| Support Level | $34.69 | $53.76 |
| Resistance Level | $42.96 | $66.24 |
| Average True Range (ATR) | 1.90 | 2.47 |
| MACD | 0.14 | 0.41 |
| Stochastic Oscillator | 21.21 | 95.72 |
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.